Health & bio
Denali's tividenofusp alfa decision due April 5
FDA was scheduled to decide on Denali Therapeutics' tividenofusp alfa for Hunter syndrome on April 5, marking a watershed moment for rare lysosomal-storage disease.
Primary sources · 1
FDA was scheduled to decide on Denali Therapeutics' tividenofusp alfa for Hunter syndrome on April 5, marking a watershed moment for rare lysosomal-storage disease.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.